ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Identification and validation of hub genes in CD5-positive diffuse large B-cell lymphoma

Yang, Ming; Niu, Xingjian; Yang, Xudong; Sun, Yutian; Su, Wenjia; Zhang, Jing; Wu, Qianjiang; Wang, Yiran; Zhang, Qingyuan*; Ji, Hongfei*哈尔滨医科大学; 1
Experimental Biology and Medicine2023-9DOI: 10.1177/15353702231151987
14阅读
引用收藏
分享

摘要

CD5+ diffuse large B-cell lymphoma (DLBCL), as a significant heterogeneity category of DLBCL, is reflected in both the molecular biological and genetic levels, which in turn induces ever-changing clinical manifestations, and what mediates tumor survival mechanisms are still unclear. This study aimed to predict the potential hub genes in CD5+ DLBCL. A total of 622 patients with DLBCL diagnosed between 2005 and 2019 were included. High expression of CD5 was correlated with IPI, LDH, and Ann Arbor stage, patients with CD5-DLBCL have longer overall survival. We identified 976 DEGs between CD5-negative and positive DLBCL patients in the GEO database and performed GO and KEGG enrichment analysis. After intersecting the genes obtained through the Cytohubba and MCODE, further external verification was performed in the TCGA database. Three hub genes were screened: VSTM2B, GRIA3, and CCND2, of which CCND2 were mainly involved in cell cycle regulation and JAK-STAT signaling pathways. Analysis of clinical samples showed that the expression of CCND2 was found to be correlated with CD5 (p = 0.001), and patients with overexpression of CCND2 in CD5+ DLBCL had poor prognosis (p = 0.0455). Cox risk regression analysis showed that, for DLBCL, CD5, and CCND2 double positive was an independent poor prognostic factor (HR: 2.545; 95% CI: 1.072-6.043; p = 0.034). These findings demonstrate that CD5 and CCND2 double-positive tumors should be stratified into specific subgroups of DLBCL with poor prognosis. CD5 may regulate CCND2 through JAK-STAT signaling pathways, mediating tumor survival. This study provides independent adverse prognostic factors for risk assessment and treatment strategies for newly diagnosed DLBCL.

学科与关键词

关键词
CD5CCND2diffuse large B-cell lymphomaprognosishub genes
相关
加载中…
  • Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma
    Chen, Wanjun; Liang, Weijie; He, Yongjian; Liu, Chixiang; Chen, Hongtian; Lv, Piao; Yao, Yuan; Zhou, Huayou*MEDICAL ONCOLOGY, 2022, 39(4): 44.被引 5
  • 原发CD5阳性的弥漫大B细胞淋巴瘤10例
    张倩; 张红宇; 钟凤鸾; 张文丽; 许蕾; 冯佳; 孟庆祥中国实验血液学杂志, 2013, (02): 399-402.
  • A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study
    Cai, Jun; Tian, Xiaopeng; Ma, Shuyun; Zhong, Liye; Li, Wenyu; Wang, Liang; Guo, Linlang; Li, Zhihua; Wu, Yudan; Zhong, Guangzheng; Huang, Huiqiang; Xia, Zhongjun; Xia, Yi; Liu, Panpan; Su, Ning; Fang, Yu; Zhang, Yuchen; Cai, Qingqing*British Journal of Cancer, 2021, 125(3): 402-412.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Experimental Biology and Medicine
发表日期
2023-09
卷期
第 248 卷, 第 17 期
页码
1469-1478
DOI
10.1177/15353702231151987
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81730074, 81672599, 82002781]; China Postdoctoral Science Foundation [2018M641858]; Hei Long Jiang Postdoctoral Foundation [LBH-Z18115]; Knowledge Innovation Program of Harbin Medical University [31041180112]; National Science Foundation of Heilongjiang Province of China for Returness [LC2017037]

作者

  • Y

    Yang, Ming (第一作者)

    harbin med univ

  • N

    Niu, Xingjian

    harbin med univ

查看全部 10 位作者收起作者
  • Y

    Yang, Xudong

    harbin med univ

  • S

    Sun, Yutian

    harbin med univ

  • S

    Su, Wenjia

    1 · harbin med univ

  • Z

    Zhang, Jing

    harbin med univ

  • W

    Wu, Qianjiang

    harbin med univ

  • W

    Wang, Yiran

    harbin med univ

  • Z

    Zhang, Qingyuan (通讯)

    harbin med univ

  • J

    Ji, Hongfei (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417